Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Science ; 380(6652): 1349-1356, 2023 06 30.
Article in English | MEDLINE | ID: mdl-37384702

ABSTRACT

Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo-electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.


Subject(s)
Chagas Disease , Topoisomerase II Inhibitors , Triazoles , Trypanosoma , Trypanosomiasis, African , Animals , Humans , Mice , Chagas Disease/drug therapy , Cryoelectron Microscopy , DNA Topoisomerases, Type II/metabolism , Trypanosoma/drug effects , Topoisomerase II Inhibitors/chemistry , Topoisomerase II Inhibitors/pharmacology , Topoisomerase II Inhibitors/therapeutic use , Triazoles/chemistry , Triazoles/pharmacology , Triazoles/therapeutic use , Trypanosomiasis, African/drug therapy , Drug Evaluation, Preclinical
2.
PLoS Negl Trop Dis ; 16(9): e0010779, 2022 09.
Article in English | MEDLINE | ID: mdl-36170238

ABSTRACT

Amphotericin B is increasingly used in treatment of leishmaniasis. Here, fourteen independent lines of Leishmania mexicana and one L. infantum line were selected for resistance to either amphotericin B or the related polyene antimicrobial, nystatin. Sterol profiling revealed that, in each resistant line, the predominant wild-type sterol, ergosta-5,7,24-trienol, was replaced by other sterol intermediates. Broadly, two different profiles emerged among the resistant lines. Whole genome sequencing then showed that these distinct profiles were due either to mutations in the sterol methyl transferase (C24SMT) gene locus or the sterol C5 desaturase (C5DS) gene. In three lines an additional deletion of the miltefosine transporter gene was found. Differences in sensitivity to amphotericin B were apparent, depending on whether cells were grown in HOMEM, supplemented with foetal bovine serum, or a serum free defined medium (DM). Metabolomic analysis after exposure to AmB showed that a large increase in glucose flux via the pentose phosphate pathway preceded cell death in cells sustained in HOMEM but not DM, indicating the oxidative stress was more significantly induced under HOMEM conditions. Several of the lines were tested for their ability to infect macrophages and replicate as amastigote forms, alongside their ability to establish infections in mice. While several AmB resistant lines showed reduced virulence, at least two lines displayed heightened virulence in mice whilst retaining their resistance phenotype, emphasising the risks of resistance emerging to this critical drug.


Subject(s)
Antiprotozoal Agents , Leishmania mexicana , Mice , Animals , Amphotericin B/pharmacology , Leishmania mexicana/metabolism , Nystatin , Serum Albumin, Bovine/metabolism , Sterols , Oxidative Stress , Polyenes , Transferases/metabolism , Glucose , Fatty Acid Desaturases/metabolism , Antiprotozoal Agents/pharmacology
3.
J Med Chem ; 65(17): 11776-11787, 2022 09 08.
Article in English | MEDLINE | ID: mdl-35993839

ABSTRACT

Human African Trypanosomiasis (HAT) is a vector-borne disease caused by kinetoplastid parasites of the Trypanosoma genus. The disease proceeds in two stages, with a hemolymphatic blood stage and a meningo-encephalic brain stage. In the latter stage, the parasite causes irreversible damage to the brain leading to sleep cycle disruption and is fatal if untreated. An orally bioavailable treatment is highly desirable. In this study, we present a brain-penetrant, parasite-selective 20S proteasome inhibitor that was rapidly optimized from an HTS singleton hit to drug candidate compound 7 that showed cure in a stage II mouse efficacy model. Here, we describe hit expansion and lead optimization campaign guided by cryo-electron microscopy and an in silico model to predict the brain-to-plasma partition coefficient Kp as an important parameter to prioritize compounds for synthesis. The model combined with in vitro and in vivo experiments allowed us to advance compounds with favorable unbound brain-to-plasma ratios (Kp,uu) to cure a CNS disease such as HAT.


Subject(s)
Quinolines , Trypanosoma , Trypanosomiasis, African , Animals , Cryoelectron Microscopy , Disease Models, Animal , Humans , Mice , Proteasome Inhibitors/pharmacology , Proteasome Inhibitors/therapeutic use , Quinolines/pharmacology , Quinolines/therapeutic use , Trypanosomiasis, African/drug therapy , Trypanosomiasis, African/parasitology
4.
PLoS Pathog ; 17(7): e1009734, 2021 07.
Article in English | MEDLINE | ID: mdl-34310651

ABSTRACT

Animal African Trypanosomiasis (AAT) is a debilitating livestock disease prevalent across sub-Saharan Africa, a main cause of which is the protozoan parasite Trypanosoma congolense. In comparison to the well-studied T. brucei, there is a major paucity of knowledge regarding the biology of T. congolense. Here, we use a combination of omics technologies and novel genetic tools to characterise core metabolism in T. congolense mammalian-infective bloodstream-form parasites, and test whether metabolic differences compared to T. brucei impact upon sensitivity to metabolic inhibition. Like the bloodstream stage of T. brucei, glycolysis plays a major part in T. congolense energy metabolism. However, the rate of glucose uptake is significantly lower in bloodstream stage T. congolense, with cells remaining viable when cultured in concentrations as low as 2 mM. Instead of pyruvate, the primary glycolytic endpoints are succinate, malate and acetate. Transcriptomics analysis showed higher levels of transcripts associated with the mitochondrial pyruvate dehydrogenase complex, acetate generation, and the glycosomal succinate shunt in T. congolense, compared to T. brucei. Stable-isotope labelling of glucose enabled the comparison of carbon usage between T. brucei and T. congolense, highlighting differences in nucleotide and saturated fatty acid metabolism. To validate the metabolic similarities and differences, both species were treated with metabolic inhibitors, confirming that electron transport chain activity is not essential in T. congolense. However, the parasite exhibits increased sensitivity to inhibition of mitochondrial pyruvate import, compared to T. brucei. Strikingly, T. congolense exhibited significant resistance to inhibitors of fatty acid synthesis, including a 780-fold higher EC50 for the lipase and fatty acid synthase inhibitor Orlistat, compared to T. brucei. These data highlight that bloodstream form T. congolense diverges from T. brucei in key areas of metabolism, with several features that are intermediate between bloodstream- and insect-stage T. brucei. These results have implications for drug development, mechanisms of drug resistance and host-pathogen interactions.


Subject(s)
Trypanosoma brucei brucei/metabolism , Trypanosoma congolense/metabolism , Animals , Lipid Regulating Agents/pharmacology , Mice , Trypanosoma brucei brucei/drug effects , Trypanosoma congolense/drug effects , Trypanosomiasis, African
5.
Nat Commun ; 12(1): 1052, 2021 02 16.
Article in English | MEDLINE | ID: mdl-33594070

ABSTRACT

The parasitic protist Trypanosoma brucei is the causative agent of Human African Trypanosomiasis, also known as sleeping sickness. The parasite enters the blood via the bite of the tsetse fly where it is wholly reliant on glycolysis for the production of ATP. Glycolytic enzymes have been regarded as challenging drug targets because of their highly conserved active sites and phosphorylated substrates. We describe the development of novel small molecule allosteric inhibitors of trypanosome phosphofructokinase (PFK) that block the glycolytic pathway resulting in very fast parasite kill times with no inhibition of human PFKs. The compounds cross the blood brain barrier and single day oral dosing cures parasitaemia in a stage 1 animal model of human African trypanosomiasis. This study demonstrates that it is possible to target glycolysis and additionally shows how differences in allosteric mechanisms may allow the development of species-specific inhibitors to tackle a range of proliferative or infectious diseases.


Subject(s)
Glycolysis/drug effects , Phosphofructokinases/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Trypanosoma/enzymology , Trypanosomiasis, African/metabolism , Trypanosomiasis, African/parasitology , Acute Disease , Allosteric Regulation/drug effects , Animals , Hep G2 Cells , Humans , Inhibitory Concentration 50 , Kaplan-Meier Estimate , Mice , Parasites/drug effects , Phosphofructokinases/chemistry , Phosphofructokinases/metabolism , Protein Binding/drug effects , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacokinetics , Protein Kinase Inhibitors/therapeutic use , Protein Multimerization , Structure-Activity Relationship , Trypanosoma/drug effects , Trypanosomiasis, African/drug therapy
6.
Nat Microbiol ; 5(10): 1207-1216, 2020 10.
Article in English | MEDLINE | ID: mdl-32661312

ABSTRACT

The kinetochore is a macromolecular structure that assembles on the centromeres of chromosomes and provides the major attachment point for spindle microtubules during mitosis. In Trypanosoma brucei, the proteins that make up the kinetochore are highly divergent; the inner kinetochore comprises at least 20 distinct and essential proteins (KKT1-20) that include four protein kinases-CLK1 (also known as KKT10), CLK2 (also known as KKT19), KKT2 and KKT3. Here, we report the identification and characterization of the amidobenzimidazoles (AB) protein kinase inhibitors that show nanomolar potency against T. brucei bloodstream forms, Leishmania and Trypanosoma cruzi. We performed target deconvolution analysis using a selection of 29 T. brucei mutants that overexpress known essential protein kinases, and identified CLK1 as a primary target. Biochemical studies and the co-crystal structure of CLK1 in complex with AB1 show that the irreversible competitive inhibition of CLK1 is dependent on a Michael acceptor forming an irreversible bond with Cys 215 in the ATP-binding pocket, a residue that is not present in human CLK1, thereby providing selectivity. Chemical inhibition of CLK1 impairs inner kinetochore recruitment and compromises cell-cycle progression, leading to cell death. This research highlights a unique drug target for trypanosomatid parasitic protozoa and a new chemical tool for investigating the function of their divergent kinetochores.


Subject(s)
Kinetochores/metabolism , Protein Kinase Inhibitors/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , Protozoan Proteins/antagonists & inhibitors , Trypanosoma brucei brucei/drug effects , Animals , Biomarkers , Cell Cycle/drug effects , Cell Line , Disease Models, Animal , Gene Expression , Humans , Immunophenotyping , Kinetochores/chemistry , Mice , Molecular Conformation , Molecular Dynamics Simulation , Protein Binding , Protein Kinase Inhibitors/chemistry , Protein Serine-Threonine Kinases/chemistry , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/chemistry , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Protozoan Proteins/chemistry , Structure-Activity Relationship
7.
Methods Mol Biol ; 2116: 801-817, 2020.
Article in English | MEDLINE | ID: mdl-32221957

ABSTRACT

Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it may take several months after treatment before surviving parasites become detectable in the blood. To expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive whole-body bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2).


Subject(s)
Luciferases, Firefly/chemistry , Luminescent Measurements/methods , Optical Imaging/methods , Trypanosoma brucei brucei/isolation & purification , Trypanosomiasis, African/diagnosis , Animals , Disease Models, Animal , Female , Genes, Reporter/genetics , Humans , Luciferases, Firefly/genetics , Luminescent Agents/chemistry , Luminescent Measurements/instrumentation , Mice , Parasitic Sensitivity Tests/instrumentation , Parasitic Sensitivity Tests/methods , Trypanocidal Agents/pharmacology , Trypanocidal Agents/therapeutic use , Trypanosoma brucei brucei/genetics , Trypanosomiasis, African/drug therapy , Trypanosomiasis, African/parasitology
8.
Trop Med Infect Dis ; 5(1)2020 Feb 17.
Article in English | MEDLINE | ID: mdl-32079320

ABSTRACT

Current anti-trypanosomal therapies suffer from problems of longer treatment duration, toxicity and inadequate efficacy, hence there is a need for safer, more efficacious and 'easy to use' oral drugs. Previously, we reported the discovery of the triazolopyrimidine (TP) class as selective kinetoplastid proteasome inhibitors with in vivo efficacy in mouse models of leishmaniasis, Chagas Disease and African trypanosomiasis (HAT). For the treatment of HAT, development compounds need to have excellent penetration to the brain to cure the meningoencephalic stage of the disease. Here we describe detailed biological and pharmacological characterization of triazolopyrimidine compounds in HAT specific assays. The TP class of compounds showed single digit nanomolar potency against Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense strains. These compounds are trypanocidal with concentration-time dependent kill and achieved relapse-free cure in vitro. Two compounds, GNF6702 and a new analog NITD689, showed favorable in vivo pharmacokinetics and significant brain penetration, which enabled oral dosing. They also achieved complete cure in both hemolymphatic (blood) and meningoencephalic (brain) infection of human African trypanosomiasis mouse models. Mode of action studies on this series confirmed the 20S proteasome as the target in T. brucei. These proteasome inhibitors have the potential for further development into promising new treatment for human African trypanosomiasis.

9.
PLoS Pathog ; 14(5): e1007099, 2018 05.
Article in English | MEDLINE | ID: mdl-29813133

ABSTRACT

Streptococcus pneumoniae is the major bacterial cause of community-acquired pneumonia, and the leading agent of childhood pneumonia deaths worldwide. Nasal colonization is an essential step prior to infection. The cytokine IL-17 protects against such colonization and vaccines that enhance IL-17 responses to pneumococcal colonization are being developed. The role of IL-17 in host defence against pneumonia is not known. To address this issue, we have utilized a murine model of pneumococcal pneumonia in which the gene for the IL-17 cytokine family receptor, Il17ra, has been inactivated. Using this model, we show that IL-17 produced predominantly from γδ T cells protects mice against death from the invasive TIGR4 strain (serotype 4) which expresses a relatively thin capsule. However, in pneumonia produced by two heavily encapsulated strains with low invasive potential (serotypes 3 and 6B), IL-17 significantly enhanced mortality. Neutrophil uptake and killing of the serotype 3 strain was significantly impaired compared to the serotype 4 strain and depletion of neutrophils with antibody enhanced survival of mice infected with the highly encapsulated SRL1 strain. These data strongly suggest that IL-17 mediated neutrophil recruitment to the lungs clears infection from the invasive TIGR4 strain but that lung neutrophils exacerbate disease caused by the highly encapsulated pneumococcal strains. Thus, whilst augmenting IL-17 immune responses against pneumococci may decrease nasal colonization, this may worsen outcome during pneumonia caused by some strains.


Subject(s)
Interleukin-17/immunology , Pneumonia, Pneumococcal/immunology , Receptors, Interleukin-17/genetics , Streptococcus pneumoniae/immunology , Animals , Bacteremia/immunology , Bacteremia/microbiology , Bacterial Capsules/immunology , Bacterial Capsules/ultrastructure , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/microbiology , Disease Models, Animal , Lung/cytology , Lung/enzymology , Lung/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Electron, Transmission , Microscopy, Fluorescence , Nasopharynx/microbiology , Neutrophils/cytology , Neutrophils/immunology , Peroxidase/metabolism , Phagocytosis , Pneumonia, Pneumococcal/mortality , Pneumonia, Pneumococcal/prevention & control , Receptors, Antigen, T-Cell, gamma-delta/genetics , Receptors, Antigen, T-Cell, gamma-delta/immunology , Specific Pathogen-Free Organisms , Streptococcus pneumoniae/ultrastructure
10.
PLoS One ; 13(1): e0189426, 2018.
Article in English | MEDLINE | ID: mdl-29342160

ABSTRACT

Bioluminescence has been harnessed for use in bacterial reporter systems and for in vivo imaging of infection in animal models. Strain Xen35, a bioluminescent derivative of Streptococcus pneumoniae serotype 4 strain TIGR4 was previously constructed for use for in vivo imaging of infections in animal models. We have shown that strain Xen35 is less virulent than its parent TIGR4 and that this is associated with the expression of the genes for bioluminescence. The expression of the luxA-E genes in the pneumococcus reduces virulence and down regulates the expression of the pneumococcal pilus.


Subject(s)
Fimbriae, Bacterial/genetics , Gene Expression Regulation, Bacterial , Genes, Bacterial , Streptococcus pneumoniae/genetics , Virulence/genetics , Animals , Blotting, Western , Luminescence , Mice , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Reverse Transcriptase Polymerase Chain Reaction , Streptococcus pneumoniae/pathogenicity
11.
Sci Rep ; 7(1): 6156, 2017 07 21.
Article in English | MEDLINE | ID: mdl-28733613

ABSTRACT

Protein kinases (PKs) are a class of druggable targets in Trypanosoma brucei, the causative agent of Human African Trypanosomiasis (sleeping sickness), yet little is known about which PKs are essential for survival in mammals. A recent kinome-wide RNAi screen with 176 individual bloodstream form Trypanosoma brucei lines identified PKs required for proliferation in culture. In order to assess which PKs are also potential virulence factors essential in vivo, lines were pooled, inoculated into mice, and screened for loss of fitness after 48 h RNAi. The presence of trypanosomes in the bloodstream was assessed using RNAi target sequencing (RITseq) and compared to growth in culture. We identified 49 PKs with a significant loss of fitness in vivo in two independent experiments, and a strong correlation between in vitro and in vivo loss of fitness for the majority. Nine PKs had a more pronounced growth defect in vivo, than in vitro. Amongst these PKs were several with putative functions related to stress responses mediated through the PI3K/TOR or MAPK signaling cascades, which act to protect the parasite from complement-mediated and osmotic lysis. Identification of these virulence-associated PKs provides new insights into T. brucei-host interaction and reveals novel potential protein kinase drug targets.


Subject(s)
Protein Kinases/genetics , Sequence Analysis, RNA/methods , Trypanosoma brucei brucei/pathogenicity , Trypanosomiasis, African/parasitology , Animals , Genes, Essential , Mice , Protozoan Proteins/genetics , RNA Interference , Signal Transduction , Trypanosoma brucei brucei/genetics , Trypanosomiasis, African/genetics , Trypanosomiasis, African/veterinary , Virulence Factors/genetics
12.
PLoS One ; 11(12): e0168602, 2016.
Article in English | MEDLINE | ID: mdl-27992545

ABSTRACT

Helminth parasites remain a major constraint upon human health and well-being in many parts of the world. Treatment of these infections relies upon a very small number of therapeutics, most of which were originally developed for use in animal health. A lack of high throughput screening systems, together with limitations of available animal models, has restricted the development of novel chemotherapeutics. This is particularly so for filarial nematodes, which are long-lived parasites with a complex cycle of development. In this paper, we describe attempts to visualise the immune response elicited by filarial parasites in infected mice using a non-invasive bioluminescence imaging reagent, luminol, our aim being to determine whether such a model could be developed to discriminate between live and dead worms for in vivo compound screening. We show that while imaging can detect the immune response elicited by early stages of infection with L3, it was unable to detect the presence of adult worms or, indeed, later stages of infection with L3, despite the presence of worms within the lymphatic system of infected animals. In the future, more specific reagents that detect secreted products of adult worms may be required for developing screens based upon live imaging of infected animals.


Subject(s)
Brugia pahangi/immunology , Cytokines/metabolism , Elephantiasis, Filarial/immunology , Luminescent Agents/metabolism , Luminol/metabolism , Animals , Antigens, Helminth/immunology , Disease Models, Animal , Luminescent Measurements , Lymphatic System/immunology , Male , Mice
13.
PLoS Negl Trop Dis ; 9(4): e0003714, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25881126

ABSTRACT

Peripheral infection by Trypanosoma brucei, the protozoan responsible for sleeping sickness, activates lymphocytes, and, at later stages, causes meningoencephalitis. We have videoed the cortical meninges and superficial parenchyma of C56BL/6 reporter mice infected with T.b.brucei. By use of a two-photon microscope to image through the thinned skull, the integrity of the tissues was maintained. We observed a 47-fold increase in CD2+ T cells in the meninges by 12 days post infection (dpi). CD11c+ dendritic cells also increased, and extravascular trypanosomes, made visible either by expression of a fluorescent protein, or by intravenous injection of furamidine, appeared. The likelihood that invasion will spread from the meninges to the parenchyma will depend strongly on whether the trypanosomes are below the arachnoid membrane, or above it, in the dura. Making use of optical signals from the skull bone, blood vessels and dural cells, we conclude that up to 40 dpi, the extravascular trypanosomes were essentially confined to the dura, as were the great majority of the T cells. Inhibition of T cell activation by intraperitoneal injection of abatacept reduced the numbers of meningeal T cells at 12 dpi and their mean speed fell from 11.64 ± 0.34 µm/min (mean ± SEM) to 5.2 ± 1.2 µm/min (p = 0.007). The T cells occasionally made contact lasting tens of minutes with dendritic cells, indicative of antigen presentation. The population and motility of the trypanosomes tended to decline after about 30 dpi. We suggest that the lymphocyte infiltration of the meninges may later contribute to encephalitis, but have no evidence that the dural trypanosomes invade the parenchyma.


Subject(s)
Lymphocytes/physiology , Meninges/cytology , Meninges/pathology , Microscopy/methods , Trypanosoma brucei brucei , Trypanosomiasis, African/pathology , Animals , Meningitis/parasitology , Meningitis/pathology , Mice , Trypanosomiasis, African/immunology
14.
PLoS Negl Trop Dis ; 7(8): e2384, 2013.
Article in English | MEDLINE | ID: mdl-23991236

ABSTRACT

HUMAN AFRICAN TRYPANOSOMIASIS (HAT) MANIFESTS IN TWO STAGES OF DISEASE: firstly, haemolymphatic, and secondly, an encephalitic phase involving the central nervous system (CNS). New drugs to treat the second-stage disease are urgently needed, yet testing of novel drug candidates is a slow process because the established animal model relies on detecting parasitemia in the blood as late as 180 days after treatment. To expedite compound screening, we have modified the GVR35 strain of Trypanosoma brucei brucei to express luciferase, and have monitored parasite distribution in infected mice following treatment with trypanocidal compounds using serial, non-invasive, bioluminescence imaging. Parasites were detected in the brains of infected mice following treatment with diminazene, a drug which cures stage 1 but not stage 2 disease. Intravital multi-photon microscopy revealed that trypanosomes enter the brain meninges as early as day 5 post-infection but can be killed by diminazene, whereas those that cross the blood-brain barrier and enter the parenchyma by day 21 survived treatment and later caused bloodstream recrudescence. In contrast, all bioluminescent parasites were permanently eliminated by treatment with melarsoprol and DB829, compounds known to cure stage 2 disease. We show that this use of imaging reduces by two thirds the time taken to assess drug efficacy and provides a dual-modal imaging platform for monitoring trypanosome infection in different areas of the brain.


Subject(s)
Antiprotozoal Agents/isolation & purification , Brain/parasitology , Drug Evaluation, Preclinical/methods , Host-Pathogen Interactions , Trypanosoma brucei brucei/physiology , Trypanosomiasis/parasitology , Animals , Antiprotozoal Agents/therapeutic use , Brain/pathology , Diminazene/therapeutic use , Disease Models, Animal , Female , Image Processing, Computer-Assisted , Luciferases/biosynthesis , Luciferases/genetics , Mice , Microscopy, Fluorescence, Multiphoton , Staining and Labeling , Trypanosoma brucei brucei/drug effects , Trypanosoma brucei brucei/genetics , Trypanosomiasis/drug therapy , Trypanosomiasis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...